rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Severity Over Time of Early Forms of Spondyloarthritis
Status: Not yet recruiting

Spondyloarthritis (SpA) is a group of chronic inflammatory pathologies whose progression over time is poorly defined, and in particular the clinical and instrumental elements that can predispose to a condition of disease severity are not completely known. It would be important to have an idea of what the predisposing factors are, possibly already at baseline, and possibly also at follow up, of severe disease, so as to be able to act early with more aggressive and targeted therapies on these patients, so as to achieve remission.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  age &gt;18 years; Diagnosis of SpA confirmed by the rheumatologist with duration of symptoms &lt; 2 years; Signature of the written informed consent to the study  Exclusion Criteria:  Age &lt; 18 years; Patients suffering from other rheumatic pathologies (even in overlap), or genetic diseases such as Marfan syndrome, Ehlers Danlos syndrome Any medical or psychiatric condition that in the judgment of the investigator would prevent the participant from complying with the protocol or completing the study according to the protocol. Refusal to sign the informed consent to the study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: patients with recent onset of SpA (duration of symptoms ≤2 years) and diagnosis made by the rheumatologist. - SamplingMethod: Non-Probability Sample
Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome
Status: Recruiting

This prospective pilot study of biological specimens aims to identify new prognostic and predictive biomarkers of response to standard therapy for local advanced BC, as well as to identify new targets for the development of immuno- therapeutic protocols. First aim is therefore to expand our knowledge to increase the response to preoperative treatment, intensify treatment patterns, and select patients based on clinical parameters. In this regard, it appears imperative to investigate yet under-investigated factors that might impair the response to standard therapy for local advanced BC including association to metabolic syndrome and analysis of tumoral and stromal features supporting a tumor microenvironment impenetrable to both drugs and immune system cells.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients will be treated as per standard. Inclusion criteria depend exclusively on compliance with informed consent, tumor size (only advanced stage tumors will be used for the study) and histological diagnosis. Specifically, patients with the following will be included in the proposed study:  Histological diagnosis of locally advanced Luminal or HER2+ or Triple negative breast cancer (cT2, T3, T4 N0 or any T N1, N2, N3, M0), clinical stage II to III disease. Age > 18 years Regular clinical and instrumental follow up  Informed consent form signed by enrolled patients - Availability of information from medical records:  pre/post NAC blood chemistry tests: blood count, glycemia/glycosylated hemoglobin, lipid profile (triglycerides, total cholesterol, HDL + LDL cholesterol); BMI; possible therapy with oral hypoglycaemic drugs/insulin; statins; diuretics/antihypertensive drugs; Sex hormone hormonal status (pre- or post-menopause);  Exclusion Criteria:  Prior or synchronous history of systemic malignancy. - History of homo- or contralateral breast cancer. Evidence of metastatic (Stage IV) disease. Neo-adjuvant treatment with hormonal therapy. - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Pre/postmenopausal patients diagnosed with breast cancer undergoing NCT and subsequent surgery with long follow-up. - SamplingMethod: Non-Probability Sample
Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer-HPV DNA and Other Biomarkers in Urine
Status: Recruiting

The goal of this clinical trial is

To test the sensitivity and specificity of using HPV DNA from urine for the detection of pre-cervical or/and cervical cancer.
If HPV DNA is not a promising biomarker, other biomarkers will be explored.
To develop an effective and non-invasive detection method of the pre-cervical or/and cervical cancer. in Women with menstruation.

The main question it aims to answer is:

To validate whether HPV DNA from urine could be used as a non-invasive means for the detection of pre-cervical or cervical cancer

Participants will

Join the briefing session of the study
Sign the consent form and health questionnaire
Submit the cervical medical report(s) within 3 months or perform sponsored pap smear test
Collect the urine sample

If there is a comparison group: Researchers will compare The diseased group and the healthy group according to the medical reports they provided to see if HPV DNA from urine is a promising biomarker for the detection of pre-cervical or cervical cancer

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Female aged between 18 to 65 Have menstruation Had sex before Can read and write Chinese/ English Without taking any medication (Except nutritional supplements, traditional Chinese medicine, and health care products etc.)  Exclusion Criteria:  • Subjects who used medication will be excluded from the sample collection. Moreover, subjects with visible signs of gynarcological infections (e.g. gonorrhea, trichomonas vaginalis) or suffered an HIV/ hepatitis B virus (HBV)-infection will be excluded. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer--ACTN4 and Other Biomarkers in Menstrual Blood
Status: Recruiting

The goal of this clinical trial is

To test the sensitivity and specificity of using ACTN4 from menstrual blood for the detection of pre-cervical or/and cervical cancer.
If ACTN4 is not a promising biomarker, other biomarkers will be explored.
To develop an effective and non-invasive detection method for pre-cervical or/and cervical cancer.

in Women with menstruation.

The main question it aims to answer is:

To validate whether menstrual blood could be used as a non-invasive means for the detection of pre-cervical or cervical cancer

Participants will

Join the briefing session of the study
Sign the consent form and health questionnaire
Submit the cervical medical report(s) within 3 months or perform sponsored pap smear test
Collect the menstrual blood sample

If there is a comparison group: Researchers will compare The diseased group and the healthy group according to the medical reports they provided to see if ACTN4 from menstrual blood is a promising biomarker for the detection of pre-cervical or cervical cancer

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Female aged between 18 to 65 Have menstruation Had sex before Can read and write Chinese/ English Without taking any medication (Except nutritional supplements, traditional Chinese medicine, and health care products etc.)  Exclusion Criteria:  Subjects who used medication will be excluded from the sample collection. Moreover, subjects with visible signs of gynarcological infections (e.g. gonorrhea, trichomonas vaginalis) or suffered an HIV/ hepatitis B virus (HBV)-infection will be excluded. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Multimodality Imaging and Functional Lesion Assessment in Intermediate Coronary Stenosis in Chronic Coronary Syndrome
Status: Recruiting

The aim of this prospective, investigator-initiated study is to evaluate the diagnostic accuracy and correlations between functional indices (fractional flow reserve, FFR) and morphometric indices: luminal and qualitative parameters assessed by optical coherence tomography (OCT) including minimal lumen area, plaque type, presence of thin cap fibroatheroma among patients with chronic coronary syndrome identified with intermediate grade coronary stenosis.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  18 years or older Chronic coronary syndrome defined as presence of chest pain ranked 2-3 in the Canadian Cardiovascular Society classification or positive ischemia test (exercise test, single photon emission tomography (SPECT) Intermediate grade coronary stenosis of 40-80% assessed visually in coronary angiography FFR and OCT examination of the same lesion The patient is willing to participate in the study and has provided a written informed consent  Exclusion Criteria:  Acute coronary syndrome Proximal left main lesion Ostial right coronary artery lesion Bypass of the assessed vessel Contraindications for adenosine administration Hemodynamic instability Heart insufficiency in New York Heart Association (NYHA) class IV scale Acute renal insufficiency Pregnancy - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients undergoing coronary angiogram due to chronic coronary syndrome with intermediate grade coronary stenosis. - SamplingMethod: Probability Sample
The Impact of 3D-CBCT Imaging on Nerve Injuries During Wisdom Tooth Surgery
Status: Not yet recruiting

The investigators aim to investigate if the additional information available from a 3D scan of the wisdom tooth can reduce the risk of nerve injury during wisdom tooth surgery compared to conventional 2D images.

Wisdom tooth surgery is a common surgical procedures that a significant proportion of the population will undergo. As with any other surgical procedure, there are potential complications, of which, injury to the nerve supplying feeling to the lip, chin, and tongue is the most significant. This can lead to persistent pain, tingling, or numbness that may impact a patient's ability to eat and function.

The risk of nerve injury during wisdom tooth surgery is assessed using X-ray images, which show the position of the nerve and tooth in the jawbone. 2D and 3D scans are used, which have their own advantages and disadvantages such as reduced cost and radiation dose with 2D or more information from 3D images, but it remains unclear which is better at reducing the risk of nerve injuries.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Individuals are seen in the Oral Surgery department with a 2D-OPG x-ray and a diagnosis of a mandibular wisdom tooth that requires surgical treatment. Individuals requiring a 3D-CBCT to further assess the relationship between the wisdom tooth and the inferior alveolar nerve. Individuals who are to undergo surgical treatment for their wisdom tooth regardless of the surgical approach (e.g. coronectomy or extraction) or the anaesthetic technique utilised. Individuals without any pre-existing neurological deficit of cranial nerve V (trigeminal nerve) or medical conditions or medications that may cause changes in neurosensory function. Individuals over the age of 16 and willing and able to provide valid informed consent for themselves. Individuals with adequate English comprehension to read the written PIS and consent form and understand the follow-up call questions. Individuals willing to provide contact details to allow a telephone follow-up call one week after their surgery.  Exclusion Criteria:  Individuals who do not have the capacity to consent for themselves. Individuals taking medicines or having medical conditions and disorders that impair neurosensory function. Individuals requiring wisdom tooth surgery to manage associated pathology such as cysts, fractures, or tumours where the pathological condition may interfere with the neurosensory function of the trigeminal nerve at 1 week post-operatively. Individuals who are unable to read or speak English. - HealthyVolunteers: No - Gender: All - MinimumAge: 16 Years - StdAgeList: Child, Adult, Older Adult
Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole
Status: Not yet recruiting

This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Participants must have a positive T. vaginalis rapid antigen test, wet mount, or nucleic acid amplification test (NAAT) within two weeks of available results (and have not yet been treated) that is confirmed by repeat T. vaginalis NAAT testing at study enrollment, must speak and understand English and be willing to comply with the study protocol, have a method of contact (either phone, email or social media), and be willing to be randomized.  Exclusion Criteria:  Participants will be excluded if they are pregnant/lactating, have been treated for their trichomonas infection with 5-nitroimidazoles (i.e. MTZ, SEC), used intravaginal boric acid or any other intravaginal treatment for T. vaginalis in the last 28 days, or if they have a history of a hypersensitivity reaction to 5-nitroimidazole medications. They also cannot be taking phenytoin (Dilantin) and/or warfarin (Coumadin) due to drug interactions with oral MTZ or have been previously enrolled in the study. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
High-dose Inhaled NO Therapy for the pREvenvention of NP After Cardiac Surgery Under CPB
Status: Recruiting

The primary aim of this single-center, prospective, randomized, controlled, study is to test the hypothesis that inhalation of NO 200 ppm prevents the development of nosocomial pneumonia in patients at risk after cardiac surgery under CPB. The study is interventional. Examination and treatment of patients is carried out in accordance with the approved standards of medical care for the relevant diseases. During the study, no experimental or unregistered (not approved for use) medical or diagnostic procedures in the territory of the Russian Federation will be carried out. The study includes patients admitted to the Cardiac Surgery Department of Cardiology Research Institute of Tomsk National Research Medical Center for elective surgery with CPB.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Cardiac surgery with CPB at current hospitalization. Age > 18 years. Signed informed consent  Exclusion Criteria:  Emergency surgery. Acute coronary syndrome 30 days before surgery. Surgery for active infective endocarditis requiring antibiotic therapy. Diagnosed infectious process of another localization (surgical site infection (SSI), acute and chronic urinary tract infection (active), catheter-related bloodstream infection, peritonitis, etc.). Taking antibacterial drugs for 14 days preceding surgery Other complications of the postoperative period (pneumothorax requiring pleural drainage, perioperative myocardial infarction accompanied by pulmonary edema, shock of any etiology during the current hospitalization). Potentially dialysis-dependent stage 2 and higher acute kidney injury (according to KDIGO) in the early postoperative period (the criteria for potentially dialysis-dependent acute kidney injury will include patients with stage 2 acute kidney injury and: oliguria against the background of normo-hypervolemia and resistance to loop diuretics and/ or oliguria against the background of conducting infusion therapy due to hypovolemia and resistance to loop diuretics). Continued mechanical ventilation. Delirium. Presence of tracheostomy. Patient's participation in another clinical trial at the time of screening or within the previous 3 months. Concomitant pulmonary disease with the need for respiratory support before surgery. History of malignancy or other irreversible diseases/conditions with a 6- month mortality rate >50%. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
Status: Not yet recruiting

This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors. TACE is a hepatic artery embolization technique involving the injection of a blocking agent and a chemotherapy agent to treat liver cancers. Currently, contrast enhanced magnetic resonance imaging or computed tomography are used to assess disease response 1-2 months after TACE treatment, but ultrasound may be a less expensive, earlier alternative. CEUS is an imaging procedure that uses high-frequency sound waves to generate images of the body after administering lumason, an imaging agent used to enhance visualization of blood flow on ultrasounds. CEUS is able to be performed during the TACE procedure, making it possible to evaluate treatment response earlier than standard techniques. CEUS may be an effective method to evaluate treatment response more accurately and much earlier than current standard evaluation methods.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Scheduled for TACE therapy of a liver tumor Be at least 18 years of age Be medically stable If a female of child-bearing age, must have a negative pregnancy test Have signed informed consent to participate in the study  Exclusion Criteria:  Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable Patients with known sensitivities to the components of lumason - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Efficacy of Electroacupuncture Combined With Pregabalin in the Treatment of Trigeminal Herpetic Neuralgia: a Multicenter Randomized Controlled Trial Study Protocol
Status: Recruiting

Trigeminal herpetic neuralgia is a common type of Zoster-associated Pain (ZAP), which troubles individuals in all ages and burdens society all over the world. Eleactroaupuncture (EA) is increasingly used in the treatment of ZAP due to its advantages such as low price, high safety, no adverse reactions, and high patient acceptance. Therefore, it is necessary to conduct randomized controlled trials to evaluate the effectiveness and safety of EA on ZAP and whether EA can be used as a substitute for pregabalin.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  meet the aforementioned diagnostic criteria for trigeminal ZAP, with a disease duration of 1 to 3 months; have a visual analog scale (VAS) score of 4 points ≤ VAS ≤ 7 points; be between 18 and 85 years old, regardless of gender; have clear consciousness, the ability to distinguish pain, and complete basic communication; voluntarily participate in the study, sign a written informed consent form, and fully understand the plan.  Exclusion Criteria:  do not meet the above-mentioned inclusion criteria; have concomitant herpes zoster on the trunk or extremities, or other special types of herpes zoster like meningeal herpes zoster or visceral herpes zoster; are pregnant or lactating patients; are allergic to pregabalin or acupuncture stimulation; have severe organ damage, cognitive dysfunction, mental disorder, aphasia, or other serious diseases that hinder cooperation with treatment; have severe skin diseases; have a pacemaker; have been or are currently participating in other clinical studies within the past 3 months. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 85 Years - StdAgeList: Adult, Older Adult
Hard and Soft Tissue Dimensional Change After Consecutive Extractions and Unassisted Socket Healing in the Esthetic Zone
Status: Not yet recruiting

The goal of this observational study is to evaluate the post-extraction hard and soft tissue dimension changes in patients requiring consecutive extractions and unassisted socket healing in the anterior maxilla. The main questions it aims to answer are:

Is significant alveolar ridge resorption observed at center sites after consecutive extractions
Is significant alveolar ridge resorption observed at the interalveolar septum after consecutive extractions, are different extraction sites associated with significantly different bone resorption
Is a thick or thin wall phenotype associated with the amount of bone resorption
Is soft tissue thickness change associated with the corresponding location (extraction site or interalveolar septum) and post-extraction thickness of the bone
Is the interdental papilla height significantly affected after extractions.

Participants will undergo consecutive (two) extractions and will be evaluated after subsequent unassisted socket healing for 8 weeks.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  18+ years old Require consecutive (two) teeth replacement in the anterior maxilla Signed informed consent No significant medical conditions Patients with healthy periodontal conditions or previously treated to controlled and stable conditions  Exclusion Criteria:  General medical (American Society of Anesthesiologists, ASA, class III or IV) and/or psychiatric contraindications Pregnancy or nursing Any interfering medication such as steroid therapy or bisphosphonate therapy Uncontrolled diabetes Autoimmune diseases or inflammatory diseases affecting the intraoral tissues Radiation therapy to head or neck region - HealthyVolunteers: No - Gender: All - StdAgeList: Child, Adult, Older Adult - StudyPopulation: The group is selected from the referred patient pool. Age 18 or older. Absence of significant medical conditions. Sites with a need for consecutive (two) teeth extraction in the anterior maxilla. - SamplingMethod: Non-Probability Sample
Analysis of Scapular Musculature Activation During Targeted Abdominal Contraction With Scapular Stabilization Exercises
Status: Recruiting

Muscle activation of the upper trapezius, lower trapezius and serratus anterior muscles will be measured during prone scapular retraction exercises. Then the same exercises will be performed with abdominal contraction using a stabilizer and muscle activity of the same muscles will be measured. A comparison will be made between the two conditions.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Healthy individuals between the ages of 18-30 Physical activity level of at least 5 on the Tegner activity scale.  Exclusion Criteria:  Having pathology of the shoulder and spine History of previous upper extremity surgery Body mass index greater than 24.9 Experience with core stability training. - Gender: All - MinimumAge: 18 Years - MaximumAge: 30 Years - StdAgeList: Adult - StudyPopulation: The study will include 30 healthy participants regardless of gender. - SamplingMethod: Probability Sample
The Effectiveness of Prophylactic Antibiotics for Urethral Bulking
Status: Recruiting

The goal of this clinical trial is to evaluate if prophylactic antibiotics in urethral bulking are effective in reducing postprocedural urinary tract infections.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients scheduled to undergo a urethral bulking procedure Age 18 ≥ over  Exclusion Criteria:  History of recurrent urinary tract infections Known history of urinary retention Allergies or contraindications to multiple antibiotics Inability to tolerate oral antibiotics Concomitant surgical procedures at the time of urethral bulking Pregnant or breastfeeding - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult